Table 1.

Age, ESR, symptoms, and physical examination findings by HIV interval status and gender, Zambia, 1995–2009 (N = 429 seroconverters, N = 1959 HIV-negative partners, N = 1959 HIV-positive partners).

	HIV-negative intervals						Seroconverting intervals						HIV-positive intervals						p values*
	Total		Men		Women		Total		Men		Women		Total		Men		Women
	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR
Age	31	25–37	34	29–40	27	22–33	28	24–34	31	36–28	25	22–30	30	25–35	33	39–28	27	22–32	a, b, c, d, e
ESR*	13	6–27	9	5–18	22	12–39	29	14–55	20	9–39	38	20–70	34	17–64	25	12–47	42	23–72	a, b, c, d, e
	Proportion of HIV-negative intervals						Proportion of seroconverting intervals						Proportion of HIV-positive intervals
Symptoms	N = 18674	%	N = 9900	%	N = 8774	%	N = 417	%	N = 189	%	N = 228	%	N = 18189	%	N = 7844	%	N = 10345	%
Malaria syndrome																			a, b, c, d, e
Treated†	1379	7.4	681	6.9	698	8	100	24	54	28.6	46	20.2	2043	11.2	904	11.5	1139	11
Self-reported‡	1801	9.6	1015	10.3	786	9	93	22.3	49	25.9	44	19.3	2101	11.6	1114	14.2	987	9.5
Asthenia																			a, b, e
Treated	101	0.5	57	0.6	44	0.5	6	1.4	2	1.1	4	1.8	228	1.3	97	1.2	131	1.3
Self-reported	1053	5.6	585	5.9	468	5.3	50	12.0	25	13.2	25	11.0	1465	8.1	769	9.8	696	6.7
Night sweats																			a, c , d, e
Treated	166	0.9	140	1.4	26	0.3	5	1.2	3	1.6	2	0.9	470	2.6	310	4.0	160	1.5
Self-reported	611	3.3	463	4.7	148	1.7	30	7.2	21	11.1	9	3.9	985	5.4	637	8.1	348	3.4
Chronic diarrhea																			a, e
Treated	29	0.2	21	0.2	8	0.1	1	0.2	0	0.0	1	0.4	212	1.2	132	1.7	80	0.8
Self-reported	49	0.3	28	0.3	21	0.2	8	1.9	3	1.6	5	2.2	194	1.1	109	1.4	85	0.8
Oral Candidiasis																			a, c, e
Treated	5	0.0	5	0.1	0	0.0	1	0.2	0	0.0	1	0.4	87	0.5	51	0.7	36	0.3
Self-reported	38	0.2	11	0.1	27	0.3	2	0.5	0	0.0	2	0.9	98	0.5	50	0.6	48	0.5
Physical examination findings	N = 9804	%	N = 4846	%	N = 4958	%	N = 361	%	N = 166	%	N = 195	%	N = 9274	%	N = 4479	%	N = 4795	%
Bilateral adenopathy
Axillary	252	2.6	153	3.2	99	2.0	25	6.9	18	10.8	7	3.6	1705	18.4	1119	25.0	586	12.2	a, b ,c, d, e
Inguinal	1241	12.7	932	19.2	309	6.2	95	26.3	59	35.5	36	18.5	3539	38.2	2380	53.1	1159	24.2	a, b, c, d, e
Neck	86	0.9	39	0.8	47	0.9	12	3.3	5	3.0	7	3.6	538	5.8	275	6.1	263	5.5	a, b
Unilateral adenopathy
Axillary	469	4.8	392	8.1	77	1.6	21	5.8	14	8.4	7	3.6	1140	12.3	860	19.2	280	5.8	b, c, d, e
Inguinal	799	8.1	686	14.2	113	2.3	21	5.8	16	9.6	5	2.6	873	9.4	595	13.3	278	5.8	b, c, d, e
Neck	206	2.1	137	2.8	69	1.4	11	3.0	4	2.4	7	3.6	690	7.4	481	10.7	209	4.4	b, c, e
Dermatosis	564	5.8	409	8.4	155	3.1	14	3.9	6	3.6	8	4.1	795	8.6	498	11.1	297	6.2	b, c, e

a. Significant difference between HIV-negative and seroconverting intervals (p<0.05)

b. Significant difference between HIV-positive and seroconverting intervals (p<0.05)

c. Significant difference between men and women among HIV-negative intervals (p<0.05)

d. Significant difference between men and women among seroconverting intervals (p<0.05)

e. Significant difference between men and women among HIV-positive intervals (p<0.05)

Wilcoxon tests for continuous variables; chi-square tests for categorical variables

^*For ESR data, N = 956 HIV-negative intervals; N = 684 Seroconverting intervals; N = 956 HIV-positive intervals

^†Treated malaria = treated suspected or treated confirmed malaria

^‡Self-reported malaria = self-reported suspected or self-reported confirmed malaria